ZEMAIRA for chronic augmentation and
maintenance therapy in adults with A1-PI deficiency
and clinical evidence of emphysema
Connect with us
Meet with your CSL Behring Associate Director of Corporate Accounts.
Meet with your CSL Behring Associate Director of Corporate Accounts.
Schedule a meetingFormulary kit
Review product-specific resources for ZEMAIRA.
FormularyDecisions® members can download the ZEMAIRA Dossier and additional ZEMAIRA resources from FormularyDecisions.com.
About A1AT deficiency (AATD)
AATD is a hereditary condition characterized by low levels of the protein alpha1 antitrypsin (A1AT). AATD results in uninhibited neutrophil elastase activity, an imbalance that can lead to progressive degenerative and destructive changes in the lungs, including emphysema.1
AATD can be challenging to diagnose because it shares a similar clinical presentation with more common conditions like chronic obstructive pulmonary disease (COPD) and asthma.1,2 AATD is the most common genetic risk factor for COPD.2 In fact, current guidelines recommend screening all individuals diagnosed with COPD or unexplained bronchiectasis for AATD regardless of age or ethnicity.3
What is ZEMAIRA?
ZEMAIRA is an alpha1-proteinase inhibitor (A1-PI) indicated for chronic augmentation and maintenance therapy in adults with A1-PI deficiency and emphysema.
The effect of augmentation therapy with ZEMAIRA or any A1-PI product on pulmonary exacerbations and on the progression of emphysema in A1-PI deficiency has not been demonstrated in randomized, controlled clinical studies.
ZEMAIRA is not indicated for lung disease patients in whom severe A1-PI deficiency has not been established.
Please see full prescribing information for ZEMAIRA.
What are the key benefits?
ZEMAIRA is a once-per-week infusion that is proven to elevate and maintain serum levels of A1AT.4*
Dotted line represents an A1AT level of 11 µM, a threshold presumed to provide therapeutically relevant anti–neutrophil elastase protection.
*Clinical data demonstrating the long-term effects of chronic augmentation therapy with ZEMAIRA are not available. The effect of augmentation therapy with ZEMAIRA or any A1-PI product on pulmonary exacerbations and the progression of emphysema in A1AT deficiency have not been demonstrated in randomized, controlled clinical studies.
†Average infusion time is based on an infusion rate of 0.08 mL/kg/min for a 75 kg (165 lb) patient. Individual experiences may vary.
LOW INFUSION
VOLUMES
allow for treatment in as little as 15 minutes†
CAN BE
STORED SAFELY
at room temperature
HIGHLY PURIFIED
AUGMENTATION
THERAPY
used in AATD treatment for >16 years with no confirmed cases of virus transmission5
Want to learn more?
Meet with your CSL Behring Associate Director of Corporate Accounts.
